[Malignant lymphoma associated with HIV infection]

Area of Science:

• Oncology
• Infectious Diseases
• Immunology

Background:

• Human Immunodeficiency Virus (HIV) infection is associated with an increased risk of various neoplasms.
• Malignant lymphomas are a significant concern in HIV-infected individuals, necessitating further investigation into their characteristics and treatment outcomes.

Purpose of the Study:

• To analyze the incidence, clinical features, and therapeutic outcomes of malignant tumors in HIV-infected patients, with a specific focus on malignant lymphomas.
• To provide initial data on HIV-associated neoplasms to guide future research and clinical management.

Main Methods:

• A multi-center retrospective study was conducted.
• Data from 119 HIV-infected patients with malignant tumors (excluding Kaposi's sarcoma) were analyzed.

Main Results:

• Malignant non-Hodgkin's lymphoma was the most frequent diagnosis (82.5%), often occurring in patients with severe immunodeficiency, high-grade malignancy, and extranodal or visceral spread.
• Lymphoblastic non-Hodgkin's lymphoma showed a better prognosis, earlier diagnosis, and less extranodal involvement.
• Median survival for non-Hodgkin's lymphoma patients treated with chemotherapy was 6 months, with 13% achieving remission over 12 months.

Conclusions:

• Despite a generally poor prognosis in HIV-associated lymphomas, palliative chemotherapy can be justified and may lead to life-prolonging remissions.
• Further research into the management of these aggressive malignancies in immunocompromised patients is warranted.